🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Biobank - Investigating the Gut Microbiota, Genetics, Epigenetics and Metabolites

Recruitingn/aAges 18 Years - anyAllChinese University of Hong Kong
NCT03855657 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Inflammatory bowel disease (IBD) affects 1 in 500 to 1,000 people in the West. Previously a disease predominantly of the West, there is now a marked increase in the incidence of ulcerative colitis (UC) and Crohn's disease (CD) in Asia, with an estimated prevalence of 1 in 3,000 and 1 in 10,000 respectively\[1\]. The rapid increase of IBD in Asian raising concern of investigators. Therefore setting up a large scale biobank with comprehensive clinical data is require.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient ≥18 with a diagnosis of Crohn's disease or ulcerative colitis * Informed Consent obtained Exclusion Criteria: * Known current infection with an enteric pathogen * Previously been diagnosed with IBD (Control) * Have a first of second degree relative with IBD (Control)
💊

What it tests

  • Not listed
📍

Where

1 site
Prince of Wales Hospital
Hong Kong, Hong Kong
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy